JPS5821623A - 抗原抗体複合体沈着疾患治療剤 - Google Patents

抗原抗体複合体沈着疾患治療剤

Info

Publication number
JPS5821623A
JPS5821623A JP56118928A JP11892881A JPS5821623A JP S5821623 A JPS5821623 A JP S5821623A JP 56118928 A JP56118928 A JP 56118928A JP 11892881 A JP11892881 A JP 11892881A JP S5821623 A JPS5821623 A JP S5821623A
Authority
JP
Japan
Prior art keywords
gamma globulin
antigen
deposition
treated
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56118928A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0250884B2 (enExample
Inventor
Tetsuzo Sugizaki
杉崎　徹三
Shinichi Morisue
森末　新一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP56118928A priority Critical patent/JPS5821623A/ja
Priority to DE19823228007 priority patent/DE3228007A1/de
Priority to DE3250068A priority patent/DE3250068C2/de
Priority to IT67956/82A priority patent/IT1156482B/it
Publication of JPS5821623A publication Critical patent/JPS5821623A/ja
Publication of JPH0250884B2 publication Critical patent/JPH0250884B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP56118928A 1981-07-28 1981-07-28 抗原抗体複合体沈着疾患治療剤 Granted JPS5821623A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP56118928A JPS5821623A (ja) 1981-07-28 1981-07-28 抗原抗体複合体沈着疾患治療剤
DE19823228007 DE3228007A1 (de) 1981-07-28 1982-07-27 Arzneimittel zur behandlung von systemischem lupus erythematodes und primaerer glomerulonephritis
DE3250068A DE3250068C2 (enExample) 1981-07-28 1982-07-27
IT67956/82A IT1156482B (it) 1981-07-28 1982-07-28 Composizione per il trattamento del lupus eritematoso sistemico e glomerulonefrite primaria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56118928A JPS5821623A (ja) 1981-07-28 1981-07-28 抗原抗体複合体沈着疾患治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP57057875A Division JPS5821624A (ja) 1982-04-06 1982-04-06 慢性関節リウマチの治療剤

Publications (2)

Publication Number Publication Date
JPS5821623A true JPS5821623A (ja) 1983-02-08
JPH0250884B2 JPH0250884B2 (enExample) 1990-11-05

Family

ID=14748668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56118928A Granted JPS5821623A (ja) 1981-07-28 1981-07-28 抗原抗体複合体沈着疾患治療剤

Country Status (3)

Country Link
JP (1) JPS5821623A (enExample)
DE (2) DE3250068C2 (enExample)
IT (1) IT1156482B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101427A (ja) * 1982-11-30 1984-06-12 Teijin Ltd 腎疾患治療剤
JPS59190922A (ja) * 1983-04-12 1984-10-29 Green Cross Corp:The 炎症治療予防剤
JPS60185726A (ja) * 1983-12-07 1985-09-21 アンステイテユ　メリユ− 免疫調整医薬
JPS61155335A (ja) * 1984-12-28 1986-07-15 Green Cross Corp:The 免疫調節剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763135A (en) * 1971-11-08 1973-10-02 Baxter Laboratories Inc Gamma globulin production from cohn fraction iii using polyethylene glycol
DE2508132C3 (de) * 1974-03-08 1980-10-16 Teijin Ltd., Osaka (Japan) Verfahren zur Herstellung von Humanimmunglobulin-Derivaten und parenteral applizierbare Lösung hiervon
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4124576A (en) * 1976-12-03 1978-11-07 Coval M L Method of producing intravenously injectable gamma globulin

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101427A (ja) * 1982-11-30 1984-06-12 Teijin Ltd 腎疾患治療剤
JPS59190922A (ja) * 1983-04-12 1984-10-29 Green Cross Corp:The 炎症治療予防剤
JPS60185726A (ja) * 1983-12-07 1985-09-21 アンステイテユ　メリユ− 免疫調整医薬
JPS61155335A (ja) * 1984-12-28 1986-07-15 Green Cross Corp:The 免疫調節剤

Also Published As

Publication number Publication date
DE3228007A1 (de) 1983-02-17
IT8267956A0 (it) 1982-07-28
JPH0250884B2 (enExample) 1990-11-05
DE3228007C2 (enExample) 1992-01-30
IT8267956A1 (it) 1984-01-28
DE3250068C2 (enExample) 1992-08-06
IT1156482B (it) 1987-02-04

Similar Documents

Publication Publication Date Title
Spitler et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin
Thompson et al. Drug‐induced lichen planus
US6074642A (en) Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
Lawrence et al. Two patterns of skin ulceration induced by methotrexate in patients with psoriasis
DE3855869T2 (de) Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
Goodfellow et al. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen‐induced arthritis
Gilliam et al. Fibrinolytic therapy for vasculitis of atrophie blanche
MXPA98000760A (en) Methods for the treatment of asthma allergy
BR112021008778A2 (pt) Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
JP2730889B2 (ja) 単クローン性抗体療法
Kelley et al. The nephrotic syndrome in children: I. Clinical response to nitrogen mustard therapy
Kürschner et al. IFN-gamma receptor-Ig fusion proteins. Half-life, immunogenicity, and in vivo activity
Walsh et al. Effects of cetirizine on human eosinophil and neutrophil activation in vitro
Avasthi et al. Benign monoclonal gammaglobulinemia and glomerulonephritis
KR100533399B1 (ko) 경구투여용제제
Tani et al. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models
JPS5821623A (ja) 抗原抗体複合体沈着疾患治療剤
Bao et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes
CA2091134C (en) Therapeutic agent for threatened abortion
CA1341425C (en) Antibodies to angiogenin: immunotherapeutic agents
La Via et al. Studies on Fc receptor function: I. IgG-mediated inhibition of B lymphocyte activation by T-dependent and T-independent antigens
US5520914A (en) Antibodies to angiogenin: immunotherapeutic agents
US4465670A (en) Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor
WO1983004260A1 (fr) Enzyme analogue de la pepsine de leucocyte humain et agent therapeutique contenant cette enzyme en tant qu'ingredient effectif pour le traitement de troubles allergiques, de maladies auto-immunitaires et de tumeurs
JPS6341890B2 (enExample)